Iconix Wins EPA Contract for Chemogenomics-Based Toxicity Screens

NEW YORK, Jan. 6 (GenomeWeb News) - Iconix Pharmaceuticals has won a contract from the Environmental Protection Agency to screen chemicals for toxicity using its chemogenomics platform, the company said today.

Iconix, based in Mountain View, Calif., will use its DrugMatrix platform to work work with the EPA's Computational Toxicology Research Program to study the potential toxicity of five undisclosed chemicals.

DrugMatrix contains profiles of more than 650 chemical compounds, including information about gene expression, biological pathways, toxicology, and pharmacology.